Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.50 |
| ▸ | RAB9A | P51151 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NSD2 | O96028 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18410443 | 0.80 | ROCK1 (0.62) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL18233010 | 0.80 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL18236213 | 0.78 | SCN5A (0.52) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL18235552 | 0.75 | NPC1 (0.51) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL18407350 | 0.74 | PTPN1 (0.54) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL18407355 | 0.73 | LMNA (0.48) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL18233039 | 0.72 | PTPN1 (0.51) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL20173265 | 0.70 | MMP2 (0.51) | NPC1RAB9ASMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL4250752 | 0.69 | KCNK9 (0.81) | NPC1RAB9ASMN1; SMN2TP53KCNK9 | |
| SCHEMBL18236201 | 0.69 | PTPN1 (0.55) | NPC1RAB9ASMN1; SMN2TP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301255-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20170022150-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-01-26 | — | — | US | disclosed |
| US-20170022150-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301255-B2 | Hepatitis B antiviral agents | HAVCR2, ZC3HAV1, SLC10A1 | NPC1 607/4885RAB9A 1332/4885SMN1; SMN2 4641/4885 |
| US-20170022150-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, ZC3HAV1, SLC10A1 | NPC1 607/4885RAB9A 1332/4885SMN1; SMN2 4641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.